These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6334656

  • 1. Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.
    Colombo MP, Arioli I, Parmiani G.
    Int J Cancer; 1984 Dec 15; 34(6):807-13. PubMed ID: 6334656
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.
    Colombo MP, Parenza M, Parmiani G.
    Cancer Immunol Immunother; 1985 Dec 15; 20(3):198-204. PubMed ID: 3851699
    [Abstract] [Full Text] [Related]

  • 3. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML, Parenza M, Parmiani G.
    J Natl Cancer Inst; 1983 Feb 15; 70(2):291-7. PubMed ID: 6571938
    [Abstract] [Full Text] [Related]

  • 4. Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.
    Sensi M, Grazioli L, Parmiani G.
    Cancer Immunol Immunother; 1986 Feb 15; 21(3):199-204. PubMed ID: 2938737
    [Abstract] [Full Text] [Related]

  • 5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 15; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 6. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G, Sensi ML, Carbone G, Colombo M, Pierotti M, Ballinari D, Hilgers J, Hilkens J.
    Int J Cancer; 1982 Mar 15; 29(3):323-32. PubMed ID: 7068280
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden.
    Formelli F, Rossi C, Sensi ML, Parmiani G.
    Int J Cancer; 1988 Dec 15; 42(6):952-7. PubMed ID: 3263956
    [Abstract] [Full Text] [Related]

  • 8. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
    Rosenstein M, Eberlein TJ, Rosenberg SA.
    J Immunol; 1984 Apr 15; 132(4):2117-22. PubMed ID: 6607955
    [Abstract] [Full Text] [Related]

  • 9. DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A BALB/c anti-DBA/2 serum which lyses the tumor and blocks BALB/c anti-tumor and anti-DBA/2 effectors.
    Ballinari D, Grazioli L, Sensi ML, Borrello MG, Parmiani G.
    Int J Cancer; 1985 Nov 15; 36(5):617-22. PubMed ID: 3877002
    [Abstract] [Full Text] [Related]

  • 10. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
    Dennis JW, Laferté S, Man MS, Elliott BE, Kerbel RS.
    Int J Cancer; 1984 Nov 15; 34(5):709-16. PubMed ID: 6437992
    [Abstract] [Full Text] [Related]

  • 13. Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
    Sensi M, Bergomi M, Formelli F, Parmiani G.
    Int J Cancer; 1990 Dec 15; 46(6):1088-94. PubMed ID: 2249896
    [Abstract] [Full Text] [Related]

  • 14. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
    Fuyama S, Komatsu H, Arai S.
    Cell Immunol; 1991 Oct 01; 137(1):200-15. PubMed ID: 1679379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. ACA-1, a new differentiation antigen of activated lymphoid cells.
    Nesterenko VG, Novikova TK, Fontalin LN, Rubakova EI, Gruner S, Wechnik E, Sidorova EV.
    Cell Immunol; 1983 Jul 15; 79(2):253-64. PubMed ID: 6223705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.